The International Alliance Dedicated to Advancing the Practice of AI-Enabled Precision Medicine
with game-changing AI-Enabled Treatment-Matching Tools that pair precise, genomically-founded treatments to each person's unique cancer
Members / Supporting Organizations
.png&height=48&width=268.5&scale=0.866&x=0.04&y=46.57)
.png&height=116.399)
.jpg&height=74.399)
.jpg&height=47&width=268.5&scale=0.671&x=0.099&y=33.198)
.png&height=62.4)
.jpg&height=48)
.jpg&height=67.2)
.png&height=66)
.png&height=180)
.jpg&height=76.8)
Mission & Purpose
The non-profit International Alliance of AI-Enabled Treatment-Matching Tools represents medical technology innovators, research scientists, oncologists, health economists and patient advocates worldwide, who have a genuine concern for others and a desire to save lives by helping to accelerate the widespread adoption of the same technologies that oncologists at leading academic institutions use to identify treatments that have a solid genomic rationale, and a higher likelihood of clinical success.
To achieve this, we must acknowledge that technological innovation is no longer a step-based, linear process progressing from basic to clinical research to general use. In reality, technological innovation occurrs exponentially fast, despite our institutions' inability to absorb these changes. This ever-widening gap hinders and unnecessarily delays our ability to realize the potential of AI-enabled tools that can speed-up and enhance care and reduce wasteful spending on high-cost, ineffective treatments.
Solving for this requires that we rethink the way we prioritize which technological changes to embrace -- given our institution's limited bandwidth for absorbing change -- and create a more efficient process by which to vet them. Moreover, we must realize that creating evidence-informed practices is a dynamic process, and not a static one. As such, the age-old requirement to have a complete evidence base before an innovation can be put into practice no longer makes sense; especially, when you consier that today's researchers are able to generate and adapt to evidence at all stages of technology implementation.
The IAATT promotes AI-Enabled Treatment-Matching Tools by working closely with lawmakers, policymakers, agency officials and health system / payer representatives to advance its priorities through education, advocacy, and guidance.
Education
Our educational initiative provides awareness and understanding about the scientific basis and usefulness of
AI-Enabled Treatment-Matching Tools
Advocacy
Our advocacy efforts are intended to encourage the support for the rapid development and safe deployment of
AI-Enabled Treatment-Matching Tool
Guidance
Our guidance helps to modernize regulatory, coverage, reimbursement and access policies as they relate to AI-Enabled Treatment-Matching Tools
Technology so Revolutionary ... it Warranted a New CPT Code
The American Medical Association's Current Procedural Terminology coding convention provides a uniform language for coding medical services and procedures for clinicians and health insurers alike.
On July 1, 2023 the AMA issued a new CPT Code (0794T) Pharmaco-oncologic Algorithmic Treatment Ranking to recognize the increasing use of AI augmentation to create personalized cancer treatments. This "tracking" code covers "patient-specific, assistive, rules-based algorithms for ranking pharmaco-oncologic treatment options based on the patient's tumor-specific cancer marker information... "
.jpg)
Real-World Case StudY: Ai-Enabled Sarcoma management
There are few problems in oncology as challenging as sarcoma as it is not one disease but a set of rare and diverse diseases, each having a distinct behavior. As such, they must be treated on a patient-specific basis, as most standard-of-care therapies fall short of expectations. Comprehensive genomic diagnosis however can uncover otherwise hidden actionable intelligence -- a virtual design spec -- that enables us to identify synthetic lethal opportunities and create customized treatments to effectively target these vulnerabilities. Ken was diagnosed with sarcoma at age 58. He's had twelve DNA/RNA gene sequencings, to identify variants, monitor treatment progress and power the several AI-enabled treatment-matching tools that generated deep "engineering-level" insight into the molecular structure and workings of his unique cancer; thereby identifying numerous cancer-support vulnerabilities to attack and multiple pathways for lethal anti-cancer agents. Having this otherwise unavailable knowledge reassured and empowered Ken. This facilitated more informed and meaningful shared decision-making and helped ken develop the confidence he needed to pursue a more aggressive, science-based treatment plan. It certainly influenced many of his critical treatment decisions: -- Selecting high-clinical-value treatments early saved valuable time and reduced Ken's time-to-care. -- Monitoring Ken's dynamic genomic profile enabled his oncologists to slow disease progression. -- Identifying low-clinical-value drugs avoided wastefully spending of finite patient and payer dollars. This N-of-One case study portends well as to the clinical utility (usefulness and value) of these important tools..jpg)
real-World Patient Case Study: Orlando
Undifferentiated Sarcoma of Unknown Primary
Learn about Orlando, a middle-aged LA-based professional with a rare sarcoma who has had twelve staged (solid tumor and blood-based) DNA and RNA gene sequencings -- that were then used to power seven AI-enabled treatment-matching tools. These tools generated deep, "engineering-level" genomic insight into the molecular inner workings of Orlando's unique cancer that led to the identification of multiple cancer support vulnerabilites and pathways for lethal anti-cancer agents. This knowledge resulted in critical treatment adjustments that benefited Orlando, his oncology team and his health plan. Identifying high-clinical-value treatments early, reduced Orlando's time-to-treatment. Identifying low-clinical-value drugs helped avoid wastefully spending tens of thousands of finite patient, health system and payer dollars. This portends well, as it relates to the usefulness and value (clinical utility) of these game-changing tools.real-World Patient Case Study: Orlando
Undifferentiated Sarcoma of Unknown Primary
Learn about Orlando, a middle-aged LA-based professional with a rare sarcoma who has had twelve staged (solid tumor and blood-based) DNA and RNA gene sequencings -- that were then used to power seven AI-enabled treatment-matching tools. These tools generated deep, "engineering-level" genomic insight into the molecular inner workings of Orlando's unique cancer that led to the identification of multiple cancer support vulnerabilites and pathways for lethal anti-cancer agents. This knowledge resulted in critical treatment adjustments that benefited Orlando, his oncology team and his health plan. Identifying high-clinical-value treatments early, reduced Orlando's time-to-treatment. Identifying low-clinical-value drugs helped avoid wastefully spending tens of thousands of finite patient, health system and payer dollars. This portends well, as it relates to the usefulness and value (clinical utility) of these game-changing tools.real-World Patient Case Study: Orlando
Undifferentiated Sarcoma of Unknown Primary
Learn about Orlando, a middle-aged LA-based professional with a rare sarcoma who has had twelve staged (solid tumor and blood-based) DNA and RNA gene sequencings -- that were then used to power seven AI-enabled treatment-matching tools. These tools generated deep, "engineering-level" genomic insight into the molecular inner workings of Orlando's unique cancer that led to the identification of multiple cancer support vulnerabilites and pathways for lethal anti-cancer agents. This knowledge resulted in critical treatment adjustments that benefited Orlando, his oncology team and his health plan. Identifying high-clinical-value treatments early, reduced Orlando's time-to-treatment. Identifying low-clinical-value drugs helped avoid wastefully spending tens of thousands of finite patient, health system and payer dollars. This portends well, as it relates to the usefulness and value (clinical utility) of these game-changing tools.
★ ★ ★ ★ ★
"Personalized medicine is the wave of the future. Unfortunately, all too often, it is the exception rather than the standard of care. This initiative will help move things forward."Santosh Kesari, MD, PhD
Chair/Professor, Translational Neurosciences Providence Saint John’s Cancer Institute★ ★ ★ ★ ★
"Patient-centric oncology achieves superior outcomes by leveraging the scientific insight that is available only from AI-augmented molecular diagnostic clinical support tools."Michael Castro, MD
Pioneering Cancer "Engineer" and KOL Chief Medical Officer, Cellworks Group★ ★ ★ ★ ★
"With more than 300 available anti-cancer drugs, millions of treatment combinations exist that simply can not be identified and fully considered without AI-enabled tools."Razelle Kurzrock, MD
World-Renowned Precision Oncology Leader Chief Medical Officer, WIN Consortium★ ★ ★ ★ ★
"New AI-enabled precision medicine tools benefit everyone as they amplify the appeal of N-of-1 research focused on individual, not average, responses to treatment."Nicholas Shork, PHD
Deputy Director / Distinguished Professor Translational Genomics Research Institute★ ★ ★ ★ ★
"The use of AI-augmented oncology support tools will help medication pre-authorization teams avoid wasteful spending on high-cost, low- clinical-value treatments."Mark Fendrick, MD
Professor / Director, University of Michigan Center for Value-Based Insurance Design★ ★ ★ ★ ★
"Personalized medicine technology, which has global appeal, should be more broadly integrated into routine medical practice, for the betterment of public health, worldwide."Jeanette McCarthy, MPH, PhD
Professor / Executive Team - Duke Center for Applied Genomics and Precision Medicine★ ★ ★ ★ ★
"Having the availability to practice precision medicine, and doing less, may create new responsibility and liability constructs for clinicians, health systems and payers alike."Adam Russo, ESQ
Distinguished ERISA Attorney Co-Founder / CEO - The Phia Group★ ★ ★ ★ ★
"The age of personal genomics, precision medicine and AI-enabled medical decision making is here, transforming our lives for the good. We must accelerate its adoption."dENNIS gRISHiN, pHD
Research Fellow - Harvard University Dana-Farber Cancer Institute★ ★ ★ ★ ★
"Medicine is more than just science, as it involves applying it to the human condition . AI-enabled technologies further this mission by exploiting computational biology."David Lawrence, MD
Former CEO and Chairmain Kaiser Foundation Health Plan / Hospitals
.jpg&height=105.6){kind=logo}